Skip to Main Content

Paper Details

Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer.
Mol Oncol
3
2023
Author NameAffiliation
Fengshen KuoMemorial Sloan Kettering Cancer Center
Luc G T MorrisMemorial Sloan Kettering Cancer Center
  • 1 - 2

Datasets

Release 1.2